Taken together, emodin may inhibit the activity of MyD88 and block transmission of the TLR signalling pathway to limit the proliferation of immune cells, suppress inflammatory responses induced by PI3K/Akt/NF-κB in microglia, and improve the clinical symptoms of EAE/MS. Here, MYD88 is linked to myeloid sarcoma.